Prostatype Genomics AB (OSTO:PROGEN) Dividends per Share : kr0.00 (TTM As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Dividends per Share?

Prostatype Genomics AB's dividends per share for the three months ended in Jun. 2023 was kr0.00. Its dividends per share for the trailing twelve months (TTM) ended in Jun. 2023 was kr0.00. Its Dividend Payout Ratio for the three months ended in Jun. 2023 was 0.00. As of today, Prostatype Genomics AB's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Prostatype Genomics AB Dividends per Share Historical Data

The historical data trend for Prostatype Genomics AB's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Dividends per Share Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

Dividends per Share

Prostatype Genomics AB Quarterly Data
	Jun18	Jun19	Mar20	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Dividends per Share	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Prostatype Genomics AB's Dividends per Share

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prostatype Genomics AB's Dividend Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Dividend Yield % falls into.

Prostatype Genomics AB Dividends per Share Calculation

Dividends paid to per common share.

Prostatype Genomics AB (OSTO:PROGEN) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Prostatype Genomics AB's Dividend Payout Ratio for the quarter that ended in Jun. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2023 )	/	EPS without NRI (Q: Jun. 2023 )
	=	0	/	-0.052
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Prostatype Genomics AB Dividends per Share Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (OSTO:PROGEN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

PGO:Germany

Address

Gustaf III:s Boulevard 34, Solna, SWE, 169 73

Website

https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines